IDH Mutation Analysis in Ewing Sarcoma Family Tumors
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Isocitrate dehydrogenase (IDH) catalyzes the oxidative decarboxylation of isocitrate to yield α-ketoglutarate (α-KG) with production of reduced nicotinamide adenine dinucleotide (NADH). Dysfunctional IDH leads to reduced production of α-KG and NADH and increased production of 2-hydroxyglutarate, an oncometabolite. This results in increased oxidative damage and stabilization of hypoxia-inducible factor α, causing cells to be prone to tumorigenesis. Methods: This study investigated IDH mutations in 61 Ewing sarcoma family tumors (ESFTs), using a pentose nucleic acid clamping method and direct sequencing. Results: We identified four cases of ESFTs harboring IDH mutations. The number of IDH1 and IDH2 mutations was equal and the subtype of IDH mutations was variable. Clinicopathologic analysis according to IDH mutation status did not reveal significant results. Conclusions: This study is the first to report IDH mutations in ESFTs. The results indicate that ESFTs can harbor IDH mutations in previously known hot-spot regions, although their incidence is rare. Further validation with a larger case-based study would establish more reliable and significant data on prevalence rate and the biological significance of IDH mutations in ESFTs.
Abstract
Background: Isocitrate dehydrogenase (IDH) catalyzes the oxidative decarboxylation of isocitrate to yield α-ketoglutarate (α-KG) with production of reduced nicotinamide adenine dinucleotide (NADH). Dysfunctional IDH leads to reduced production of α-KG and NADH and increased production of 2-hydroxyglutarate, an oncometabolite. This results in increased oxidative damage and stabilization of hypoxia-inducible factor α, causing cells to be prone to tumorigenesis. Methods: This study investigated IDH mutations in 61 Ewing sarcoma family tumors (ESFTs), using a pentose nucleic acid clamping method and direct sequencing. Results: We identified four cases of ESFTs harboring IDH mutations. The number of IDH1 and IDH2 mutations was equal and the subtype of IDH mutations was variable. Clinicopathologic analysis according to IDH mutation status did not reveal significant results. Conclusions: This study is the first to report IDH mutations in ESFTs. The results indicate that ESFTs can harbor IDH mutations in previously known hot-spot regions, although their incidence is rare. Further validation with a larger case-based study would establish more reliable and significant data on prevalence rate and the biological significance of IDH mutations in ESFTs.
참고문헌 (14)
- van Maldegem AM, "The clinical use of biomarkers as prognostic factors in Ewing sarcoma", Clin Sarco-ma Res, 2, pp.7~ (2012)
- Schaap FG, "Mutations in the isocitrate dehydrogenase genes IDH1 and IDH2 in tumors", Adv Anat Pathol, 20, pp.32~38 (2013)
- Lu C, "Induction of sarcomas by mutant IDH2", Genes Dev, 27, pp.1986~1998 (2013)
- Yan H, "IDH1 and IDH2 mutations in gliomas", N Engl J Med, 360, pp.765~773 (2009)
- Abbas S, "Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia : prevalence and prognostic value", Blood, 116, pp.2122~2126 (2010)
- Abdel-Wahab O, "Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias", Cancer Res, 70, pp.447~452 (2010)
- Amary MF, "IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours", J Pathol, 224, pp.334~343 (2011)
- Liu X, "Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1", Cancer Med, 2, pp.803~814 (2013)
- Kato Kaneko M, "Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone", Cancer Sci, 105, pp.744~748 (2014)
- Fletcher CD, "WHO classification of tumours of soft tissue and bone" (2013), IARC Press
- Rasheed S, "Characterization of a newly derived human sarcoma cell line(HT-1080)", Cancer, 33, pp.1027~1033 (1974)
- Kerr DA, "Molecular distinction of chondrosarcoma from chondroblastic osteosarcoma through IDH1", 2 mutations, 2013, pp.37, 787~795
- Arai M, "Frequent IDH1", 2 mutations in intracranial chondrosarcoma : a possible diagnostic clue for its differentiation from chordoma, 2012, pp.29, 201~206
- 이현주, "Comparison of Direct Sequencing, PNA Clamping-Real Time Polymerase Chain Reaction, and Pyrosequencing Methods for the Detection of EGFR Mutations in Non-small Cell Lung Carcinoma and the Correlation with Clinical Responses to EGFR Tyrosine Kinase Inhibitor Treatment", Journal of Pathology and Translational Medicine, 47(1), pp.52~60 (2013), 대한병리학회